Intranasal Administration of Mycobacterium bovis BCG Induces Superior Protection against Aerosol Infection with Mycobacterium tuberculosis in Mice

ABSTRACT Despite the widespread use of Mycobacterium bovis BCG, the only licensed vaccine against tuberculosis (TB), TB remains a global epidemic. To assess whether more direct targeting of the lung mucosa by respiratory immunization would enhance the potency and longevity of BCG-induced anti-TB protective immunity, the long-term impact of intranasal (i.n.) BCG vaccination was compared to conventional subcutaneous (s.c.) immunization by using a mouse model of pulmonary tuberculosis. Although significantly improved protection in the lung was seen at early time points (2 and 4 months postvaccination) in i.n. BCG-immunized mice, no differences in pulmonary protection were seen 8 and 10 months postvaccination. In contrast, in all of the study periods, i.n. BCG vaccination induced significantly elevated protective splenic responses relative to s.c. immunization. At five of nine time points, we observed a splenic protective response exceeding 1.9 log10 protection relative to the s.c. route. Furthermore, higher frequencies of CD4 T cells expressing gamma interferon (IFN-γ) and IFN-γ/tumor necrosis factor alpha, as well as CD8 T cells expressing IFN-γ, were detected in the spleens of i.n. vaccinated mice. Using PCR arrays, significantly elevated levels of IFN-γ, interleukin-9 (IL-9), IL-11, and IL-21 expression were also seen in the spleen at 8 months after respiratory BCG immunization. Overall, while i.n. BCG vaccination provided short-term enhancement of protection in the lung relative to s.c. immunization, potent and extremely persistent splenic protective responses were seen for at least 10 months following respiratory immunization.

[1]  W. Busey,et al.  Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. , 2015, The American review of respiratory disease.

[2]  J. Sterne,et al.  Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  E. Gormley,et al.  Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination , 2014, Clinical and Vaccine Immunology.

[4]  J. Renauld,et al.  IL-9–mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation , 2013, The Journal of experimental medicine.

[5]  W. Hinrichs,et al.  Devices and formulations for pulmonary vaccination , 2013, Expert opinion on drug delivery.

[6]  R. Steinman,et al.  Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract , 2013, The Journal of experimental medicine.

[7]  S. Lockhart,et al.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial , 2013, The Lancet.

[8]  A. Ramsay,et al.  Prime–boost approaches to tuberculosis vaccine development , 2012, Expert review of vaccines.

[9]  W. Jacobs,et al.  Formulation of a mmaA4 Gene Deletion Mutant of Mycobacterium bovis BCG in Cationic Liposomes Significantly Enhances Protection against Tuberculosis , 2012, PloS one.

[10]  Donata Medaglini,et al.  Distribution of Primed T Cells and Antigen-Loaded Antigen Presenting Cells Following Intranasal Immunization in Mice , 2011, PloS one.

[11]  A. Murphy,et al.  Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung , 2011, Proceedings of the National Academy of Sciences.

[12]  J. Renauld,et al.  IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells , 2009, Proceedings of the National Academy of Sciences.

[13]  S. Morris,et al.  The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis. , 2008, Vaccine.

[14]  P. Giri,et al.  Is intranasal vaccination a feasible solution for tuberculosis? , 2008, Expert review of vaccines.

[15]  B. Kreiswirth,et al.  Mycobacterium bovis BCG Immunization Induces Protective Immunity against Nine Different Mycobacterium tuberculosis Strains in Mice , 2008, Infection and Immunity.

[16]  J. Renauld,et al.  IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis , 2008, Cell Death and Differentiation.

[17]  P. Hopewell,et al.  IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. , 2008, Clinical immunology.

[18]  J. Ernst,et al.  Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs , 2008, The Journal of experimental medicine.

[19]  Mario Roederer,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.

[20]  G. Khuller,et al.  Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. , 2006, The Journal of infection.

[21]  W. Bishai,et al.  Paucibacillary Tuberculosis in Mice after Prior Aerosol Immunization with Mycobacterium bovis BCG , 2004, Infection and Immunity.

[22]  Z. Xing,et al.  Single Intranasal Mucosal Mycobacterium bovis BCG Vaccination Confers Improved Protection Compared to Subcutaneous Vaccination against Pulmonary Tuberculosis , 2004, Infection and Immunity.

[23]  J. Tavernier,et al.  Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. , 2000, Blood.

[24]  C S Berkey,et al.  The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. , 1995, Pediatrics.

[25]  C S Berkey,et al.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. , 1994, JAMA.

[26]  D. Smith,et al.  BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. , 1993, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[27]  I. Orme,et al.  Aerogenic vaccination of mice with Mycobacterium bovis BCG. , 1986, Tubercle.

[28]  M. J. Lefford Induction and expression of immunity after BCG immunization , 1977, Infection and immunity.

[29]  J. Jernigan,et al.  Aerosolized BCG (Tice strain) treatment of bronchogenic carcinoma: phase I study. , 1975, Journal of the National Cancer Institute.

[30]  C. Meyer,et al.  Aerosol BCG treatment of carcinoma metastatic to the lung: A phase I study , 1975, Cancer.

[31]  Smith Dw,et al.  The influence of vaccination on the course of experimental airborne tuberculosis in mice. , 1974 .

[32]  S. Rosenthal,et al.  Aerogenic BCG vaccination against tuberculosis in animal and human subjects. , 1968, The Journal of asthma research.

[33]  G. Middlebrook Immunological aspects of airborne infection: reactions to inhaled antigens. , 1961, Bacteriological reviews.

[34]  S. Lockhart,et al.  Safety and efficacy of MVA 85 A , a new tuberculosis vaccine , in infants previously vaccinated with BCG : a randomised , placebo-controlled phase 2 b trial , 2013 .

[35]  J. Renauld,et al.  IL-9 Induces Differentiation of TH17 Cells and Enhances Function of FoxP3+Natural Regulatory T Cells , 2009 .

[36]  H. McShane,et al.  Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective , 2003 .

[37]  G. Colditz,et al.  Relationship between bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  D. Smith,et al.  The influence of vaccination on the course of experimental airborne tuberculosis in mice. , 1974, Journal of the Reticuloendothelial Society.